[et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.27.4″ custom_padding=”0px||||false|false” global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.27.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” width=”100%” max_width=”2000px” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” pac_dcm_carousel_specific_module_num=”0″ global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text module_class=”sidinsidetextblock” _builder_version=”4.27.4″ _module_preset=”default” text_font=”Montserrat||||||||” text_text_color=”#000000″ text_font_size=”20px” text_line_height=”1.4em” header_font=”|700|||||||” header_text_color=”gcid-59c0cf7e-d456-40ab-8674-8a143836e98c” header_font_size=”48px” header_2_font=”|700|||||||” header_2_text_color=”gcid-59c0cf7e-d456-40ab-8674-8a143836e98c” header_2_font_size=”42px” header_3_font=”|700|||||||” header_3_text_color=”gcid-59c0cf7e-d456-40ab-8674-8a143836e98c” header_3_font_size=”36px” header_4_font=”|700|||||||” header_4_text_color=”gcid-59c0cf7e-d456-40ab-8674-8a143836e98c” header_4_font_size=”32px” header_5_font=”|700|||||||” header_5_text_color=”gcid-59c0cf7e-d456-40ab-8674-8a143836e98c” header_5_font_size=”28px” header_6_font=”|700|||||||” header_6_text_color=”gcid-59c0cf7e-d456-40ab-8674-8a143836e98c” header_6_font_size=”24px” hover_enabled=”0″ text_font_size_tablet=”18px” text_font_size_phone=”16px” text_font_size_last_edited=”on|phone” header_font_size_tablet=”42px” header_font_size_phone=”36px” header_font_size_last_edited=”on|tablet” header_2_font_size_tablet=”36px” header_2_font_size_phone=”32px” header_2_font_size_last_edited=”on|tablet” header_3_font_size_tablet=”32px” header_3_font_size_phone=”28px” header_3_font_size_last_edited=”on|tablet” header_4_font_size_tablet=”28px” header_4_font_size_phone=”24px” header_4_font_size_last_edited=”on|tablet” header_5_font_size_tablet=”24px” header_5_font_size_phone=”20px” header_5_font_size_last_edited=”on|tablet” header_6_font_size_tablet=”20px” header_6_font_size_phone=”18px” header_6_font_size_last_edited=”on|tablet” global_colors_info=”{%22gcid-59c0cf7e-d456-40ab-8674-8a143836e98c%22:%91%22header_text_color%22,%22header_2_text_color%22,%22header_3_text_color%22,%22header_4_text_color%22,%22header_5_text_color%22,%22header_6_text_color%22%93}” sticky_enabled=”0″]<\/p>\n
Dr. Roger Lo is Professor of the Departments of Medicine and Molecular & Medical Pharmacology, Associate Chief of Dermatology, and Director of the Dermatology STAR Residency at UCLA\u2019s David Geffen School of Medicine. He earned his BS in Biology (Honors and Distinction, 1994, Stanford University) and his MD-PhD degrees from the Tri-institutional (Weill Cornell, Memorial Sloan-Kettering, and Rockefeller) Program in 2002. After residency and postdoc training at UCLA, he joined the UCLA faculty in 2008, received tenure (UC Full Time Equivalent) in 2014, and rose to full professor in 2016. In 2013, the American Association for Cancer Research (AACR) recognized Dr. Lo with the 33rd Annual Award for Outstanding Achievement in Cancer Research for providing the major scientific rationale toward the use of BRAF and MEK inhibitors in combination to effectively treat melanoma \u2013 a therapeutic approach that is now globally considered the standard of care for melanoma and approved by the US FDA for cancer-agnostic indication. Studies from his group have led to multiple clinical trials and ten patents. His group has been credited with the first studies on the roles of tumor heterogeneity, genomic instability, and immune microenvironment in determining clinical responses to current melanoma therapies. His primary research articles have been published in Nature, Nature Medicine, New England Journal of Medicine, Cancer Discovery, Cancer Cell, Cell, and Immunity. In 2017, AACR recognized Dr. Lo\u2019s translational melanoma research with the inaugural AACR-Waun Ki Hong Award for Outstanding Achievement in Cancer Research. The American Society for Clinical Investigation inducted Dr. Lo in 2012 and the Association of American Physicians in 2024. ClarivateAnalytics (formerly Thomson Reuters) named Dr. Lo a Highly Cited Researcher (HCR). He served on the Editorial Board of Cancer Discovery and chaired the Education Program of the 2021 AACR Annual Meeting. Currently, Dr. Lo serves as the Vice Chair of the Melanoma Committee in the Southwest Oncology Group (SWOG) and on the Scientific Committee of the European Society for Medical Oncology (ESMO).<\/p>\n
The William Montagna Lecture is given annually at the SID\u2019s Annual Meeting.\u00a0 The award is intended to honor and reward young investigators with primary emphasis given to researchers in skin biology.<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
William Montagna Lecture: Translational Concepts from Melanoma Therapeutic Resistance Mechanisms About Roger Lo, MD\/PhD Thursday, May 14, 11:30 AM \u2013 12:00 PM Dr. Roger Lo is Professor of the Departments of Medicine and Molecular & Medical Pharmacology, Associate Chief of Dermatology, and Director of the Dermatology STAR Residency at UCLA\u2019s David Geffen School of Medicine. […]<\/p>\n","protected":false},"author":1,"featured_media":20206438,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"Roger Lo, MD\/PhD","_et_gb_content_width":"","footnotes":""},"categories":[18],"tags":[],"dipi_cpt_category":[],"class_list":["post-20206436","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-2026-annual-meeting-named-lectures"],"yoast_head":"\n